A single viral protein HCMV US2 affects antigen presentation and intracellular iron homeostasis by degradation of classical HLA class I and HFE molecules

被引:40
作者
Arieh, SVB
Laham, N
Schechter, C [1 ]
Yewdell, JW
Coligan, JE
Ehrlich, R
机构
[1] Tel Aviv Univ, Dept Cell Res & Immunol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel
[2] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA
[3] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood-2002-07-2158
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
HFE is a nonclassical class I molecule that associates with beta2-microglobulin (beta2m) and with the transferrin receptor. HFE accumulates in transferrin-containing endosomes, and its overexpression in human cell lines correlates with decreased transferrin receptor (TFR)-mediated iron uptake and decreased intracellular iron pools. A mutation that interferes with proper folding and assembly of HFE complexes results in a severe iron-overload disease hereditary hemochromatosis. We previously suggested that viruses could also interfere with iron metabolism through the production of proteins that inactivate HFE, similarly to classical class proteins. In particular, we demonstrated in a transient expression system that human cytomegalovirus (HCMV) US2 targeted HFE for proteasomal degradation. Here we demonstrate that the stable expression of HCMV US2 in HEK 293 cells constitutively expressing HFE leads to loss of HFE expression both intracellularly and on the cell surface, and the significant reduction of classical class I expression. Both HFE and classical class I molecules are targeted to degradation via a similar pathway. This HCMV US2-mediated degradation of HFE leads to increased intracellular iron pools as indicated by reduced synthesis of TfR and increased ferritin synthesis. Whether this interference with regulation of iron metabolism potentiates viral replication and/or promotes damage of HCMV-infected tissues remains to be determined. Nevertheless, the deleterious effect of US2 on the expression of HFE and classical class I major histo-compatibility complexes (MHC) provides HCMV with an efficient tool for altering cellular metabolic functions, as well as supporting the escape of virus-infected cells from cytotoxic T lymphocyte (CTL)-mediated immune responses.
引用
收藏
页码:2858 / 2864
页数:7
相关论文
共 53 条
  • [1] Human cytomegalovirus inhibits antigen presentation by a sequential multistep process
    Ahn, KS
    Angulo, A
    Ghazal, P
    Peterson, PA
    Yang, Y
    Fruh, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) : 10990 - 10995
  • [2] BEERSMA MFC, 1993, J IMMUNOL, V151, P4455
  • [3] Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis
    Ben-Arieh, SV
    Zimerman, B
    Smorodinsky, NI
    Yaacubovicz, M
    Schechter, C
    Bacik, I
    Gibbs, J
    Bennink, JR
    Yewdell, JW
    Coligan, JE
    Firat, H
    Lemonnier, F
    Ehrlich, R
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (21) : 10557 - 10562
  • [4] Cagnoni C, 2000, Ann Ital Med Int, V15, P132
  • [5] Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation
    Chevalier, MS
    Daniels, GM
    Johnson, DC
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (16) : 8265 - 8275
  • [6] Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype
    Corsi, B
    Levi, S
    Cozzi, A
    Corti, A
    Altimare, D
    Albertini, A
    Arosio, P
    [J]. FEBS LETTERS, 1999, 460 (01) : 149 - 152
  • [7] DIAGNOSTIC-VALUE OF AMPLIFICATION OF HUMAN CYTOMEGALOVIRUS DNA FROM GASTROINTESTINAL BIOPSIES FROM HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
    COTTE, L
    DROUET, E
    BISSUEL, F
    DENOYEL, GA
    TREPO, C
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (08) : 2066 - 2069
  • [8] DEVAL M, 1992, J EXP MED, V176, P729
  • [9] Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
    Di Bisceglie, AM
    Bonkovsky, HL
    Chopra, S
    Flamm, S
    Reddy, RK
    Grace, N
    Killenberg, P
    Hunt, C
    Tamburro, C
    Tavill, AS
    Ferguson, R
    Krawitt, E
    Banner, B
    Bacon, BR
    [J]. HEPATOLOGY, 2000, 32 (01) : 135 - 138
  • [10] A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
    Feder, JN
    Gnirke, A
    Thomas, W
    Tsuchihashi, Z
    Ruddy, DA
    Basava, A
    Dormishian, F
    Domingo, R
    Ellis, MC
    Fullan, A
    Hinton, LM
    Jones, NL
    Kimmel, BE
    Kronmal, GS
    Lauer, P
    Lee, VK
    Loeb, DB
    Mapa, FA
    McClelland, E
    Meyer, NC
    Mintier, GA
    Moeller, N
    Moore, T
    Morikang, E
    Prass, CE
    Quintana, L
    Starnes, SM
    Schatzman, RC
    Brunke, KJ
    Drayna, DT
    Risch, NJ
    Bacon, BR
    Wolff, RK
    [J]. NATURE GENETICS, 1996, 13 (04) : 399 - 408